ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER

ECOG-ACRIN 综合白血病转化研究中心

• 批准号: 9235262
• 负责人: Ross L Levine
• 金额: $ 60万
• 依托单位: MONTEFIORE MEDICAL CENTER (BRONX, NY)
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-14 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9235262
• 关键词: Acute Promyelocytic Leukemia; Acute leukemia; Address; American College of Radiology Imaging Network; Biological; Biological Assay; Biological Markers; Biology; CLIA certified; Caring; Center for Translational Science Activities; Chronic Myeloid Leukemia; Classification; Clinic; Clinical; Clinical Investigator; Clinical Trials; Correlative Study; Data; Databases; Detection; Development; Diagnostic Procedure; Disease; Eastern Cooperative Oncology Group; Ensure; Fostering; Funding; Genome; Genomics; Goals; Hematologic Neoplasms; Hematological Disease; Investigation; Laboratories; Laboratory Finding; Laboratory Research; Laboratory Scientists; Laboratory Study; Lead; Leadership; Methods; Molecular; Molecular Profiling; National Clinical Trials Network; New York; Outcome; Pathogenesis; Patients; Phase; Pilot Projects; Protocols documentation; Research; Research Design; Research Infrastructure; Research Personnel; Residual Tumors; Resources; Risk; Science; Specimen; System; Technology; Testing; Therapeutic; Translating; Translational Research; Translations; Treatment Efficacy; Validation; base; chronic leukemia; clinical practice; cohort; computing resources; curative treatments; design; disorder subtype; epigenetic profiling; genomic platform; genomic profiles; improved outcome; innovation; leukemia; leukemia tissue bank; molecular targeted therapies; novel marker; novel therapeutics; personalized diagnostics; pre-clinical research; predicting response; programs; public health relevance; response; standard of care; success; targeted agent; targeted treatment; translational scientist; translational study; treatment strategy

DESCRIPTION (provided by applicant): We propose to create an integrated Leukemia Translational Science Center (LTSC), which will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL), the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by E. Paietta, A. Melnick and R. Levine, who collectively lead the LLC, LTRL and LTB. Through these initiatives, they have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the New York Genome Center, which provides access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including patient specimens, the LTRL, access to the New York Genome Center, genomic and epigenetic profiling databases, and scientific support. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC expects to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.

描述(由申请人提供)：我们建议创建一个综合白血病转化科学中心(LTSC)，该中心将在ECOG-ACRIN和国家临床试验网络(NCTN)内生成、协调和领导白血病转化研究。LTSC将在白血病转化实验室(LTRL)、白血病组织库(LTB)和全面的白血病数据仓库的支持下，成为白血病实验室委员会(LLC)研究的中央中心。LTSC由E.Paietta、A.Melnick和R.Levine领导，他们共同领导LLC、LTRL和LTB。通过这些举措，他们在白血病生物学的翻译研究领导和实施最先进的相关研究方面发展了广泛的跟踪记录。LTSC通过与纽约基因组中心的合作关系得到进一步加强，该中心提供高通量基因组技术、最先进的基因组平台、计算资源以及执行广泛的CLIA认证的临床基因组分析的能力。为了最大限度地加快基于最重要科学的高质量临床试验，LTSC将建立一个互动框架，吸引初级和高级临床研究人员、实验室科学家、计算生物学家、生物统计学家等，并使他们能够组成协同研究团队。LTSC将为跨学科团队提供试点项目资金，以启动这些项目和广泛的科学资源，包括患者标本、LTRL、访问纽约基因组中心、基因组和表观遗传学数据库以及科学支持。通过这种方式，LTSC将确保将转译科学研究无缝地整合到白血病临床试验中，以确定反应/结果的预测因素，识别和测试新疗法，并开发创新的相关研究，以评估抗白血病疗法的反应。通过这些活动，LTSC希望通过开发和实施个性化诊断方法、生物标记物和疗法来改变白血病护理的标准做法。